EMA approves Biocon Biologics' new monoclonal antibodies facility, renews GMP certifications for India and Malaysia sites

Jun 24, 2024

According to a press release, this facility, designed to produce multiple drug substances, will now commence the production of biosimilar Bevacizumab, enhancing the company's...

Prestige Biopharma Announces Positive Topline Results from Comparative SAMSON-II Study for HD204, a Potential Biosimilar to Avastin (bevacizumab)

Mar 24, 2026

Singapore, March 24: Prestige Biopharma today announced positive topline results from its Phase 3 SAMSON-II study evaluating HD204, a proposed biosimilar to Avastin® (bevacizumab)...